US 2003/0152628 A1 · Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core

Abstract

A tablet which comprises an inner core formulated for controlled release consisting essentially of a mixture of levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, a carrier and an inner core excipient; and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof. The subject invention also encompasses a method of treating patients suffering from Parkinson's disease or related disorders by the administration of the pharmaceutical compositions of the subject invention. The subject invention also provides methods of manufacturing the tablets of the subject invention.

Claims62

Dependent claims

A tablet which comprises

an inner core formulated for controlled release consisting essentially of a mixture of levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, a carrier and an inner core excipient component;
and
an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of a decarboxylase inhibitor and levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof.

A tablet which comprises

an inner core formulated for controlled release comprising a mixture of
(a) from about 4 mg up to about 400 mg levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, and
(b) an inner core excipient component;
and an outer layer encapsulating the inner core and formulated for immediate release comprising a mixture of
(i) a granulated admixture of from about 1 mg up to about 75 mg carbidopa and at least one excipient;
and
(ii) from about 5 mg up to about 300 mg levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt thereof, and
(iii)an outer layer excipient component.

5 more elements

Dependencies are inferred from the claim text.

Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core

Life of this patent

Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core

Life of this patent

Abstract

Claims62